Loading clinical trials...
Loading clinical trials...
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521, given orally for 16 weeks, in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
Adverse event data will be covered in Adverse events section.
Age
18 - 80 years
Sex
ALL
Healthy Volunteers
No
La Jolla, California, United States
Sacramento, California, United States
Miami, Florida, United States
Iowa City, Iowa, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Dallas, Texas, United States
Corrientes, Argentina
Start Date
February 23, 2009
Primary Completion Date
June 27, 2012
Completion Date
June 27, 2012
Last Updated
November 21, 2023
262
ACTUAL participants
Riociguat (Adempas, BAY63-2521)
DRUG
Placebo
DRUG
Lead Sponsor
Bayer
NCT07073820
NCT06899815
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07462260